← Leaderboards
Vinod Satisch Ramgolam
L2 Diagnostics, Llc
$669,015
Attributed
$1,018,236
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $319.8K · FY2018–23$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,018,236 · 3
By mechanism
R43$1,018,236 · 3
Top collaborators
- Karen G. Anthony2 shared
- Jeffrey R. Bender1 shared
Most similar at L2 Diagnostics, Llc
Same institution · by research overlap
- Karen G. Anthony$11,228,942
- Pier Francesco Cirillo$740,795
- Sahar Usmani-Brown$523,528
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroToxic EffectCytokineMouse ModelSmall Business Innovation Research GrantInflammatoryPublic HealthAdrenal Cortex HormonesResponseImmunosuppressive AgentsImmune SystemMedicinePathologyPathway InteractionsInnovationEfficacy EvaluationDoseExperimental Autoimmune EncephalomyelitisAffectImmuneAcuteInflammationBaseDisease Progression
Grant awards (4)
IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)$245,000
R43 · FY2023 · HL · contact PI
IL-23 and IL-17A mRNA-targeted oligonucleotide therapeutics in autoimmune uveitis$319,794
R43 · FY2021 · EY · contact PI
Therapeutic Inhibition of MIF to Improve Glucocorticoid Response$154,035
R43 · FY2019 · AI
Therapeutic Inhibition of MIF to Improve Glucocorticoid Response$299,407
R43 · FY2018 · AI